文献速递肝病消化道肿瘤与早癌

直接抗病毒治疗与有肝细胞癌史丙肝患者生存改善相关

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
PubMed 文献 · Gastroenterology · 2019-07-30

多中心回顾性队列研究纳入797例经治疗达完全缓解的HCV相关HCC患者,383例接受DAA治疗、414例未接受。逆概率加权分析显示DAA治疗与死亡风险显著降低相关(HR 0.54,95%CI 0.33-0.90),该关联因是否获得持续病毒学应答而异。

要点

  • DAA治疗与死亡风险显著降低相关(HR 0.54,95%CI 0.33-0.90)。
  • 获得持续病毒学应答者死亡风险降低(HR 0.29,95%CI 0.18-0.47)。
  • 未获得持续病毒学应答者死亡风险无显著降低(HR 1.13,95%CI 0.55-2.33)。

核心结论

  • 在近800例对HCC治疗达完全缓解的患者中,DAA治疗与死亡风险显著降低相关。

研究设计与样本

  • 采用Cox比例风险回归,DAA治疗作为时变协变量建模,并用逆概率加权处理信息性删失和混杂。

主要发现

  • 383例(48.1%)接受DAA治疗,414例(51.9%)未接受。
  • DAA治疗组随访941人年发生43例死亡,未治疗组随访526.6人年发生103例死亡(粗率比0.23,95%CI 0.16-0.33)。
  • 逆概率加权分析中,DAA治疗与死亡风险显著降低相关(HR 0.54,95%CI 0.33-0.90)。
  • 获得持续病毒学应答者死亡风险降低(HR 0.29,95%CI 0.18-0.47),未获得持续病毒学应答者无显著降低(HR 1.13,95%CI 0.55-2.33)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is controversy regarding the benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multicenter cohort study to compare overall survival between patients with HCV infection treated with DAAs and patients who did not receive DAA treatment for their HCV infection after complete response to prior HCC therapy. METHODS: We conducted a retrospective cohort study of patients with HCV-related HCC who achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 health care systems throughout the United States and Canada. We used Cox proportional hazards regression to determine the association between receipt of DAA therapy, modeled as a time-varying covariate, and all-cause mortality, accounting for informative censoring and confounding using inverse probability weighting. RESULTS: Of 797 patients with HCV-related HCC, 383 (48.1%) received DAA therapy and 414 (51.9%) did not receive treatment for their HCV infection after complete response to prior HCC therapy. Among DAA-treated patients, 43 deaths occurred during 941 person-years of follow-up, compared with 103 deaths during 526.6 person-years of follow-up among patients who did not receive DAA therapy (crude rate ratio, 0.23; 95% confidence interval [CI], 0.16-0.33). In inverse probability-weighted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio, 0.54; 95% CI, 0.33-0.90). This association differed by sustained virologic response to DAA therapy; risk of death was reduced in patients with sustained virologic response to DAA therapy (hazard ratio, 0.29; 95% CI, 0.18-0.47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI, 0.55-2.33). CONCLUSIONS: In an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was associated with a significant reduction in risk of death.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019. PMID: 31374215. doi:10.1053/j.gastro.2019.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。